Calcium channel blockers (CCB) was studied extensively in cardiology for their tissue
protective effect following myocardial infarction; we hypothesized that administration of
a CCB would interfere with the processes that result in exercise-induced muscle damage
(EIMD) and delayed onset muscle soreness. To investigate the effects of a CCB on a
development and recovery from EIMD, we used a double blind, placebo controlled
protocol to administer CARDIZEM CD, 240 mg/day, for 6 days to 30 college age males
and females. To induce EIMD, subjects performed 4 sets of 10 repetitions of squat, leg
press, leg extension, and leg curl. We observed no treatment related difference in CPK or
DOMS levels. Overall, peak quadriceps force (PQF) were not different between the
Placebo and Diltiazem groups, but PQF was significantly greater in the Diltiazem groups
immediately after the weight lifting bout. Average quadriceps force (AQF) values
decreased in both groups following the exercise bout; however, no difference existed
between the groups (p>.05). The Diltiazem group PQF and AQF values returned to the
pre-exercise levels 24 hours earlier than did the Placebo group. Neutrophils decreased by
21% in the Diltiazem group compare with a 1.4% increase in the Placebo group, due to
large variability in the neutrophil count at the baseline, this difference was not significant.
Lymphocytes were not affected by CCB treatment. Administration of diltiazem did not
interfere with the development of EIMD as measured by CPK release and the DOMS
scores. Diltiazem appeared to affect quadriceps force generation immediately following
the weight lifting bout and to speed the recovery of muscle force to pre-exercise level in
our sample of college age adults. Heart rate was significantly lower in the Diltiazem
group after the administration. There was no difference in either systolic or diastolic blood pressure after the administration between the Diltiazem and Placebo groups. The incidence of side effects was very low and similar in both groups. The administration of this dose and preparation of diltiazem does not change heart rate or blood pressure in a clinically significant fashion, and was well tolerated in our sample of college age adults. / Graduation date: 1997
| Identifer | oai:union.ndltd.org:ORGSU/oai:ir.library.oregonstate.edu:1957/34321 |
| Date | 22 July 1996 |
| Creators | Dvorak, Roman |
| Contributors | Harter, Rod A. |
| Source Sets | Oregon State University |
| Language | en_US |
| Detected Language | English |
| Type | Thesis/Dissertation |
Page generated in 0.0021 seconds